Clinical Pharmacology Continuing Medical Education

Episodes 1-14 of 14

• 

  RestartResume

  What is the Future of Adjuvant Therapy for Resectable Melanoma?

  MinuteCE®

  What is the Future of Adjuvant Therapy for Resectable Melanoma?

  • 

    

    Nikhil I. Khushalani, MD

    Peer

  • 

    

    Tara C. Mitchell, MD

    Peer

  1.00 program credits

• 

  RestartResume

  How Can We Best Manage irAEs During Adjuvant ICIs for Melanoma? A Case-Based Approach

  MinuteCE®

  How Can We Best Manage irAEs During Adjuvant ICIs for Melanoma? A Case-Based Approach

  • 

    

    Tara C. Mitchell, MD

    Peer

  1.00 program credits

• 

  RestartResume

  How Do Patient Characteristics Impact Adjuvant Therapy in All Stages of Resectable Melanoma?

  MinuteCE®

  How Do Patient Characteristics Impact Adjuvant Therapy in All Stages of Resectable Melanoma?

  • 

    

    Nikhil I. Khushalani, MD

    Peer

  • 

    

    Tara C. Mitchell, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Which Resected Stage II Melanoma Patients Benefit from Adjuvant ICI Therapy?

  MinuteCE®

  Which Resected Stage II Melanoma Patients Benefit from Adjuvant ICI Therapy?

  • 

    

    Nikhil I. Khushalani, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Optimizing Adjuvant Treatment for Stage IV Melanoma Patients Rendered NED After Surgery

  MinuteCE®

  Optimizing Adjuvant Treatment for Stage IV Melanoma Patients Rendered NED After Surgery

  • 

    

    Nikhil I. Khushalani, MD

    Peer

  1.00 program credits

• 

  MinuteCE®

  Resectable Melanoma: New & Emerging Adjuvant Treatments

  • 

    

    Nikhil I. Khushalani, MD

    Peer

  • 

    

    Tara C. Mitchell, MD

    Peer

  1.00 credits 6 episodes

• 

  RestartResume

  Adjuvant Treatment for BRAF+ Stage III Melanoma: A Case Study to Weigh ICI Versus Targeted Therapies

  MinuteCE®

  Adjuvant Treatment for BRAF+ Stage III Melanoma: A Case Study to Weigh ICI Versus Targeted Therapies

  • 

    

    Tara C. Mitchell, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS

  CME/CE

  Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS

  • 

    

    Paul P. Doghramji, MD, FAAFP

    Peer

  • 

    

    Rami Komrokji, MD

    Peer

  • 

    

    Allan Platt, PA-C, MMSc

    Peer

  0.25 credits

• 

  RestartResume

  Improving HPV Immunization Among US Adults: Implementing Vaccine Recommendations

  CME/CE

  Improving HPV Immunization Among US Adults: Implementing Vaccine Recommendations

  • 

    

    Margot L. Savoy, MD, MPH

    Peer

  0.50 credits

• 

  RestartResume

  NSCLC Therapy Management and Biomarker Testing

  CME/CE Broadcast Replay

  NSCLC Therapy Management and Biomarker Testing

  • 

    

    Mark Socinski, MD

    Peer

  1.00 credits

• 

  RestartResume

  The NASH Epidemic: Highlights from the AMCP 2023 Symposium

  CME/CE

  The NASH Epidemic: Highlights from the AMCP 2023 Symposium

  • 

    

    Mazen Noureddin, MD

    Peer

  0.25 credits

• 

  RestartResume

  UsHERing in New Standards of Care on HER2+ and HER2-Low MBC

  CME/CE

  UsHERing in New Standards of Care on HER2+ and HER2-Low MBC

  • 

    

    Reshma L. Mahtani, DO

    Peer

• 

  RestartResume

  Osteoporosis: The Pivotal Role That Orthopedic Surgeons Can Play in Optimizing the Bone Health of Their Postmenopausal Post-Fracture Patients

  CME/CE

  Osteoporosis: The Pivotal Role That Orthopedic Surgeons Can Play in Optimizing the Bone Health of Their Postmenopausal Post-Fracture Patients

  • 

    

    Andrea Singer, MD, FACP, CCD

    Peer

  • 

    

    Paul A. Anderson, MD

    Peer

  • 

    

    Susan V. Bukata, MD, FAOA, FAAOS

    Peer

  0.25 credits

• 

  RestartResume

  Evolving Pharmacologic Intervention for Methamphetamine Use Disorder: A Focus on ADAPT-2

  CME/CE

  Evolving Pharmacologic Intervention for Methamphetamine Use Disorder: A Focus on ADAPT-2

  • 

    

    Madhukar H. Trivedi, MD

    Peer

  • 

    

    Steven Shoptaw, PhD

    Peer

  0.25 credits